New drug approved for treating Parkinson's in Japan

A new drug used to treat Parkinson's disease has been partially approved in Japan. This was reported by Zamin.uz.

This drug is based on induced pluripotent stem cells. Information about this innovation was provided by the iPS Cell Research and Application Institute at Kyoto University.

The head of the institute, Jun Takahashi, evaluated this achievement as an important step in the field of medicine. According to him, all necessary measures are being taken to make the new treatment method a reliable standard in the near future.

The new drug contains nerve cells grown from iPS cells. These cells are transplanted into the brains of patients suffering from Parkinson's disease.

Clinical trials conducted in April 2024 showed positive changes in the health of patients. Specialists consider these results promising.

Sumitomo Pharma, the company that developed this drug, has applied to register it under the trade name Amshepur. The documents were reviewed in an accelerated procedure.

Additionally, a drug prepared on the basis of similar cells and intended to treat ischemic cardiomyopathy has also been partially approved. Currently, these two drugs are considered unique worldwide.